Arbutus Biopharma Corporation (NASDAQ:ABUS – Get Free Report) saw some unusual options trading on Tuesday. Investors purchased 5,605 call options on the company. This is an increase of 753% compared to the typical volume of 657 call options. Analyst Ratings Changes ABUS has been the subject of several analyst reports. Weiss Ratings reiterated a “sell [...]
2026 Copyright © News-Matic.com. All Rights Reserved
